A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 [canertinib] In Patients With Advanced Non-Small Cell Lung Cancer
Latest Information Update: 02 Feb 2010
At a glance
- Drugs Canertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Sep 2007 Primary endpoint 'Survival rate' has not been met.
- 01 Sep 2006 Status change
- 18 Sep 2005 New trial record.